Key result
AADs in CKD carry increased proarrhythmia risk due to altered pharmacokinetics and drug accumulation.
Why the study?
Patients with chronic kidney disease experience cardiac arrhythmias and face challenges in antiarrhythmic drug therapy due to altered pharmacokinetics and increased proarrhythmic risk.
The use of antiarrhythmic drugs in patients with chronic kidney disease requires careful consideration due to altered pharmacokinetics and an increased risk of proarrhythmias.
No takes yet. Share an insight, caveat, or question.
Supports cautious antiarrhythmic prescribing in CKD; leaves open need for dedicated dosing trials.
Potpara et al. (2016) conducted a review in Cardiac arrhythmias and chronic kidney disease. Antiarrhythmic drugs was evaluated. Antiarrhythmic drug therapy in patients with chronic kidney disease carries an increased risk for proarrhythmias due to profound alterations in pharmacokinetics and drug accumulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: